Amgen at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Amgen brings 2 presentations to ENA 2026 in Barcelona. Its program spans the interface between GLP-1 drugs and cancer and the discovery of a first-in-class MTA-cooperative PRMT5 inhibitor. The PRMT5 work describes how that inhibitor was identified and optimized.
| Organization | ENA 2026 Attendance |
|---|---|
Amgen Thousand Oaks, CA | |
Global biotechnology drugmaker with oncology medicines including bispecific T-cell engagers and the KRAS G12C inhibitor sotorasib. | Session Wed Nov 18 4:15–5:45pm Talk Thu Nov 19 1:30–1:45pm |
Find decision makers at Amgen
Tell us what you sell and we’ll find the people at Amgen most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction